Skip to main content

Clinical Trials Using Gallium Ga 68-DOTATATE

Review the clinical trials studying gallium ga 68-dotatate on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-12 of 12

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer that has Neuroendocrine Cells
Status: Active
Location: 13 locations
A Study of Pasireotide in People With Prolactinoma
Status: Active
Location: 7 locations
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Status: Active
Location: 7 locations
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Status: Active
Location: 5 locations
Lutathera for the Treatment of Inoperable, Progressive Meningioma after External Beam Radiation Therapy
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Status: Approved
Location: OHSU Knight Cancer Institute, Portland, Oregon
Zanzalintinib as Maintenance Therapy after Chemotherapy for the Treatment of High Grade Neuroendocrine Tumors
Status: Approved
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Total-body PET/CT (EXPLORER) with Different Radiotracers for the Imaging of Prostate Cancer and Neuroendocrine Tumors
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California